To understand the clinical significance of PLAA, we retrospectively collected the clinicopathological data of 79 ovarian cancer patients and their formalin-fixed and paraffin-embedded tissue samples for immunohistochemistry of PLAA protein (Fig. 1H), and found the significant association of PLAA expression with FIGO stage, lymph node metastasis, and CA125 level in patients, as shown in Table 1 Kaplan–Meier survival analysis also revealed shorter progression-free survival (PFS) in patients with low PLAA expression than that in those with high PLAA expression (Fig. 1I). The gene discussed is PLAA; the disease is metastatic malignant neoplasm in the lymph nodes.